Last reviewed · How we verify
A Pilot Study of Radioimmunodetection of 124-Iodine-labeled Humanized A33 Antibody (124I-huA33) in Patients With Colorectal Cancer
The purpose of this study is to determine whether our drug, 124I-huA33, can safely detect colorectal cancer.
Details
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 30 |
| Start date | 2004-02 |
| Completion | 2025-07-02 |
Conditions
- Colorectal Neoplasms
- Colorectal Cancer
- Colorectal Tumor
- COlorectal Carcinoma
Interventions
- Iodine-124 labeled humanized A33 (antibody)
Primary outcomes
- To determine and quantify tumor uptake of radiolabeled antibody from measurements with: — Until end of study
- PET imaging/Dosimetry — Until end of study
- Autoradiographs - tumor or biopsy samples — Until end of study
- Ex vivo radioactivity estimates - tumor, normal tissue and serum samples — Until end of study
- Toxicity defined by NCI Common Toxicity Criteria — Until end of study
Countries
United States